Clinical trial Recruiting at 1 site Phase1; Phase2 Interventional Ages 18 and up

Roxadustat for treating anemia and improving bone and mental health in hemodialysis patients

Official title: Effect of Roxadustat on Bone and Neuropsychiatric Aspects in End Stage Kidney Disease Patients on Hemodialysis

Run by Mansoura University · NCT06917950 · Data updated 2026-11-12

This study is testing if the medication Roxadustat can help improve anemia, bone health, and mental well-being in patients on hemodialysis for kidney disease.

More Depression Anxiety Disorder trials

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment46 (estimated)
SponsorMansoura University
Academic / other
Locations1 site (Al Mansurah, Dakahliya)
StatusRecruiting
StartedApril 15, 2025
Main results expectedOctober 15, 2025
Study endsNovember 1, 2025
Registry record updatedMay 11, 2025
Trial IDNCT06917950 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults over 18 years old with end-stage kidney disease on chronic hemodialysis for more than three months.

Probably not a fit

Patients who are pregnant, have malignancies, or have other specific hematological disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of Roxadustat, an oral medication, on anemia and its potential benefits for bone health and mental well-being in patients undergoing hemodialysis for end-stage kidney disease. The study aims to assess changes in bone mineral density, psychological symptoms of depression and anxiety, and nerve and muscle function through various tests and questionnaires. A total of 46 patients will be enrolled to evaluate the broader impacts of Roxadustat beyond its primary use for anemia treatment.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option that improves not only anemia but also bone health and mental health for hemodialysis patients.

How similar studies have gone: While Roxadustat has shown promise in treating anemia, its effects on bone and mental health in hemodialysis patients are less explored, making this a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The age of the patient is more than 18.
* Patients who are willing to sign informed consent.
* Patients with ESKD on chronic hemodialysis for more than 3 months.

Exclusion Criteria:

* Current pregnancy or lactation.
* Patients with pre-existing malignancy.
* patients with psychosis.
* Known history of hematological disorders or other causes of anemia other than CKD.
* Taking medications that may significantly affect or interact with bone metabolism such as osteo-anabolics or bone resorptives during the last 6 months.

Where it's running

  • Urology and Nephrology Center, Mansoura University
    Al Mansurah, Dakahliya, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.